Shorter radiation may be as safe for High-Risk prostate cancer

NCT ID NCT03938649

Ongoing Disease control Sponsor: CCTU Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a shorter, more intense radiation course (SBRT) causes fewer side effects than standard daily radiation (IMRT) in men with high-risk prostate cancer. Both groups also receive hormone therapy. The study will compare side effects, quality of life, and cancer control over 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (SBRT or IMRT) plus hormone therapy
What this could lead to: If SBRT works as well as IMRT with fewer side effects, it could offer a shorter, more convenient treatment option for high-risk prostate cancer.
What could go wrong: This is a small, early-phase study (120 people) comparing side effects, not long-term survival. SBRT may not control the cancer as well as standard radiation, and both treatments have risks like urinary or bowel problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER

Contacts and locations

Locations

Department of Clinical Oncology, Prince of Wales Hospital

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.